Post-viral cough is a type of cough originating from upper respiratory tract infections that persists after the infection is resolved. Although it was hypothesized that bronchodilators might have a role in the management of post-viral cough, a clear demonstration of their efficacy is missing. Therefore, we tested the efficacy of a combination of a β-agonist and an anticholinergic agent in reducing post-viral cough with a randomized, double blind, placebo controlled clinical trial.Patients were treated for 10 days with either a nebulized combination of salbutamol 1.875mg/0.5mL and ipratropium bromide 0.375mg/0.5mL, or a placebo, and followed up for another 10 days. Daytime and nighttime cough severity and spirometry testing were assessed before starting treatment, after 10 and 20 days.Ninety-two patients were randomized to receive placebo (. n=46) or the active treatment (. n=46); nine of them (4 in the placebo group, 5 in the active treatment group) dropped out from the study. Daytime and nighttime cough severity were significantly reduced in both groups during the study period, but the reduction was more prominent in the active treatment group vs. placebo after 10 days of treatment (. P=0.003 for day cough; P=0.061 for night cough), whereas at the end of follow-up period cough severity was comparable between the two groups. Small but significant increases in spirometric parameters were observed in the active treatment vs. placebo group, although at the end of follow-up these values returned to be comparable to placebo. The frequency of adverse events was not significantly different between the two groups of patients.We concluded that a combination of a β-agonist and an anticholinergic agent can effectively reduce post-viral cough, and can thus represent a valid option for this type of cough.

Zanasi, A., Lecchi, M., Del Forno, M., Fabbri, E., Mastroroberto, M., Mazzolini, M., et al. (2014). A randomized, placebo-controlled, double-blind trial on the management of post-infective cough by inhaled ipratropium and salbutamol administered in combination. PULMONARY PHARMACOLOGY & THERAPEUTICS, 29(2), 224-232 [10.1016/j.pupt.2014.07.008].

A randomized, placebo-controlled, double-blind trial on the management of post-infective cough by inhaled ipratropium and salbutamol administered in combination

Lecchi, MM;
2014

Abstract

Post-viral cough is a type of cough originating from upper respiratory tract infections that persists after the infection is resolved. Although it was hypothesized that bronchodilators might have a role in the management of post-viral cough, a clear demonstration of their efficacy is missing. Therefore, we tested the efficacy of a combination of a β-agonist and an anticholinergic agent in reducing post-viral cough with a randomized, double blind, placebo controlled clinical trial.Patients were treated for 10 days with either a nebulized combination of salbutamol 1.875mg/0.5mL and ipratropium bromide 0.375mg/0.5mL, or a placebo, and followed up for another 10 days. Daytime and nighttime cough severity and spirometry testing were assessed before starting treatment, after 10 and 20 days.Ninety-two patients were randomized to receive placebo (. n=46) or the active treatment (. n=46); nine of them (4 in the placebo group, 5 in the active treatment group) dropped out from the study. Daytime and nighttime cough severity were significantly reduced in both groups during the study period, but the reduction was more prominent in the active treatment group vs. placebo after 10 days of treatment (. P=0.003 for day cough; P=0.061 for night cough), whereas at the end of follow-up period cough severity was comparable between the two groups. Small but significant increases in spirometric parameters were observed in the active treatment vs. placebo group, although at the end of follow-up these values returned to be comparable to placebo. The frequency of adverse events was not significantly different between the two groups of patients.We concluded that a combination of a β-agonist and an anticholinergic agent can effectively reduce post-viral cough, and can thus represent a valid option for this type of cough.
Articolo in rivista - Articolo scientifico
Ipratropium bromide; Night cough; Post-viral cough; Salbutamol; Upper respiratory tract infection; Administration, Inhalation; Adult; Aged; Albuterol; Bronchodilator Agents; Cough; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Ipratropium; Male; Middle Aged; Respiratory Tract Infections; Spirometry; Young Adult; Pulmonary and Respiratory Medicine; Pharmacology (medical); Biochemistry (medical)
English
224
232
9
Zanasi, A., Lecchi, M., Del Forno, M., Fabbri, E., Mastroroberto, M., Mazzolini, M., et al. (2014). A randomized, placebo-controlled, double-blind trial on the management of post-infective cough by inhaled ipratropium and salbutamol administered in combination. PULMONARY PHARMACOLOGY & THERAPEUTICS, 29(2), 224-232 [10.1016/j.pupt.2014.07.008].
Zanasi, A; Lecchi, M; Del Forno, M; Fabbri, E; Mastroroberto, M; Mazzolini, M; Pisani, L; Pandolfi, P; Nava, S; Morselli Labate, A
File in questo prodotto:
File Dimensione Formato  
ipratropium 2014.pdf

Solo gestori archivio

Descrizione: Articolo principale
Dimensione 988.7 kB
Formato Adobe PDF
988.7 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/101365
Citazioni
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 12
Social impact